27631550|t|Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine - Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7
27631550|a|Parkinson's disease (PD), the second most prevalent neurodegenerative disorder with only symptomatic treatment available, is characterized by a progressive loss of dopaminergic neurons in the midbrain. Ample evidence indicated that microRNAs (miRs) could regulate post-transcriptional gene expression and neuronal disease. In the present study, we have evaluated the effects and mechanism of miR-22 in PC12 pheochromocytoma cells treated with 6-hydroxydopamine (6-OHDA) to mimic PD. RT-PCR results showed that the expression of miR-22 is downregulated in 6-OHDA - treated PC12 cells, and the overexpression of miR-22 significantly promoted the survival and proliferation of 6-OHDA - induced PC12 cells, whereas miR-22 inhibitor reversed these effects. In addition, PC12 cells were treated with miR-22 mimics or inhibitor following 6-OHDA administration, which medicated ROS production and upregulation or downregulation of caspase-3 activity, respectively. A luciferase reporter assay revealed that transient receptor potential melastatin 7 (TRPM7) is a direct target gene of miR-22, and miR-22 overexpression markedly downregulated the level of TRPM7. Strikingly, further analysis showed that miR-22 mediated 6-OHDA - induced PC12 cell survival and proliferation by targeting TRPM7. Taken together, the present study showed that miR-22 overexpression exhibited neuroprotective and reversal effects on the 6-OHDA - induced PC12 cell growth and apoptosis by targeting TRPM7.
27631550	0	20	Neuroprotective Role	T169	C0815279
27631550	24	35	MicroRNA-22	T028	C1537720
27631550	41	58	6-Hydroxydopamine	T109,T121	C0085196
27631550	61	68	Induced	T169	C0205263
27631550	69	73	Cell	T025	C0007634
27631550	74	79	Model	T050	C0684309
27631550	83	102	Parkinson's Disease	T047	C0030567
27631550	107	117	Regulation	T045	C0017263
27631550	125	131	Target	T169	C1521840
27631550	132	136	Gene	T028	C0017337
27631550	137	142	TRPM7	T028	C1425224
27631550	143	162	Parkinson's disease	T047	C0030567
27631550	164	166	PD	T047	C0030567
27631550	185	194	prevalent	T082	C0205391
27631550	195	221	neurodegenerative disorder	T047	C0524851
27631550	232	243	symptomatic	T169	C0231220
27631550	244	253	treatment	T061	C0087111
27631550	254	263	available	T169	C0470187
27631550	268	281	characterized	T052	C1880022
27631550	287	298	progressive	T169	C0205329
27631550	299	303	loss	T081	C1517945
27631550	307	327	dopaminergic neurons	T025	C1512035
27631550	335	343	midbrain	T023	C0025462
27631550	375	384	microRNAs	T114,T123	C1101610
27631550	386	390	miRs	T114,T123	C1101610
27631550	398	427	regulate post-transcriptional	T045	C1514248
27631550	428	443	gene expression	T045	C0017262
27631550	448	464	neuronal disease	T047	C0027765
27631550	481	486	study	T062	C2603343
27631550	510	517	effects	T080	C1280500
27631550	522	531	mechanism	T169	C0441712
27631550	535	541	miR-22	T028	C1537720
27631550	545	572	PC12 pheochromocytoma cells	T025	C0085262
27631550	573	580	treated	T169	C1522326
27631550	586	603	6-hydroxydopamine	T109,T121	C0085196
27631550	605	611	6-OHDA	T109,T121	C0085196
27631550	622	624	PD	T047	C0030567
27631550	626	632	RT-PCR	T063	C0599161
27631550	633	640	results	T169	C1274040
27631550	657	667	expression	T045	C0017262
27631550	671	677	miR-22	T028	C1537720
27631550	681	694	downregulated	T044	C0013081
27631550	698	704	6-OHDA	T109,T121	C0085196
27631550	707	714	treated	T169	C1522326
27631550	715	725	PC12 cells	T025	C0085262
27631550	735	749	overexpression	T045	C0017262
27631550	753	759	miR-22	T028	C1537720
27631550	774	782	promoted	T052	C0033414
27631550	787	795	survival	T043	C0007620
27631550	800	813	proliferation	T043	C0596290
27631550	817	823	6-OHDA	T109,T121	C0085196
27631550	826	833	induced	T169	C0205263
27631550	834	844	PC12 cells	T025	C0085262
27631550	854	860	miR-22	T028	C1537720
27631550	861	870	inhibitor	T080	C1999216
27631550	871	879	reversed	T169	C1555029
27631550	886	893	effects	T080	C1280500
27631550	908	918	PC12 cells	T025	C0085262
27631550	924	931	treated	T169	C1522326
27631550	937	950	miR-22 mimics	T028	C1537720
27631550	954	963	inhibitor	T080	C1999216
27631550	964	973	following	T079	C0332282
27631550	974	980	6-OHDA	T109,T121	C0085196
27631550	981	995	administration	T061	C1533734
27631550	1013	1016	ROS	T123,T196	C0162772
27631550	1017	1027	production	T044	C1148560
27631550	1032	1044	upregulation	T044	C0041904
27631550	1048	1062	downregulation	T044	C0013081
27631550	1066	1084	caspase-3 activity	T044	C1150132
27631550	1102	1112	luciferase	T116,T126,T130	C0024075
27631550	1122	1127	assay	T059	C2717977
27631550	1128	1136	revealed	T080	C0443289
27631550	1142	1183	transient receptor potential melastatin 7	T028	C1425224
27631550	1185	1190	TRPM7	T028	C1425224
27631550	1197	1203	direct	T080	C1947931
27631550	1204	1210	target	T169	C1521840
27631550	1211	1215	gene	T028	C0017337
27631550	1219	1225	miR-22	T028	C1537720
27631550	1231	1237	miR-22	T028	C1537720
27631550	1238	1252	overexpression	T045	C0017262
27631550	1262	1275	downregulated	T044	C0013081
27631550	1280	1285	level	T080	C0441889
27631550	1289	1294	TRPM7	T028	C1425224
27631550	1316	1324	analysis	T062	C0936012
27631550	1337	1343	miR-22	T028	C1537720
27631550	1353	1359	6-OHDA	T109,T121	C0085196
27631550	1362	1369	induced	T169	C0205263
27631550	1370	1374	PC12	T025	C0085262
27631550	1375	1388	cell survival	T043	C0007620
27631550	1393	1406	proliferation	T043	C0596290
27631550	1410	1419	targeting	T169	C1521840
27631550	1420	1425	TRPM7	T028	C1425224
27631550	1455	1460	study	T062	C2603343
27631550	1473	1479	miR-22	T028	C1537720
27631550	1480	1494	overexpression	T045	C0017262
27631550	1505	1520	neuroprotective	T169	C0815279
27631550	1525	1533	reversal	T169	C1555029
27631550	1534	1541	effects	T080	C1280500
27631550	1549	1555	6-OHDA	T109,T121	C0085196
27631550	1558	1565	induced	T169	C0205263
27631550	1566	1570	PC12	T025	C0085262
27631550	1571	1582	cell growth	T043	C0007595
27631550	1587	1596	apoptosis	T043	C0162638
27631550	1600	1609	targeting	T169	C1521840
27631550	1610	1615	TRPM7	T028	C1425224